Strategies for a comprehensive understanding of metabolism by aldehyde oxidase.

作者: James Matthew Hutzler , Ronald Scott Obach , Deepak Dalvie , Michael A Zientek

DOI: 10.1517/17425255.2013.738668

关键词:

摘要: Introduction: Aldehyde oxidase (AO) is a drug-metabolizing molybdo-flavoenzyme with profound species differences in expression and activity toward various substrates. The contribution of this enzyme to the metabolism clearance heterocyclic-containing xenobiotics appears have increased recent years, but has not always been identified prior clinical studies. As result, drug candidates negatively impacted development. Areas covered: This review provides most vitro vivo strategies for metabolism-pharmacokinetic (DMPK) scientist. details approaches confirmation AO as an operable metabolic pathway, estimating fraction total metabolism, identification appropriate surrogate human evaluating safety clinically relevant metabolites. Expert opinion: role new molecules continues emerge, it critical that DMPK scientists updated me...

参考文章(81)
Grant R. Wilkinson, David G. Shand, A physiological approach to hepatic drug clearance Clinical Pharmacology & Therapeutics. ,vol. 18, pp. 377- 390 ,(1975) , 10.1002/CPT1975184377
Han van de Waterbeemd, Dennis A. Smith, Barry C. Jones, Lipophilicity in PK design: methyl, ethyl, futile. Journal of Computer-aided Molecular Design. ,vol. 15, pp. 273- 286 ,(2001) , 10.1023/A:1008192010023
David A. Flockhart, Nadia Soukhova, Jae-Gook Shin, Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metabolism and Disposition. ,vol. 27, pp. 1078- 1084 ,(1999)
Christine Johnson, Christine Stubley-Beedham, J. Godfrey, P. Stell, Hydralazine: A potent inhibitor of aldehyde oxidase activity in vitro and in vivo Biochemical Pharmacology. ,vol. 34, pp. 4251- 4256 ,(1985) , 10.1016/0006-2952(85)90280-1
Joshua F. Alfaro, Jeffrey P. Jones, Studies on the mechanism of aldehyde oxidase and xanthine oxidase. Journal of Organic Chemistry. ,vol. 73, pp. 9469- 9472 ,(2008) , 10.1021/JO801053U
D. J. P. Critchley, D. J. Rance, C. Beedham, Biotransformation of carbazeran in guinea pig: Effect of hydralazine pretreatment Xenobiotica. ,vol. 24, pp. 37- 47 ,(1994) , 10.3109/00498259409043219
Nicholas A. Meanwell, Synopsis of some recent tactical application of bioisosteres in drug design. Journal of Medicinal Chemistry. ,vol. 54, pp. 2529- 2591 ,(2011) , 10.1021/JM1013693
Kunio Itoh, Mayumi Yamamura, Wataru Takasaki, Takamitsu Sasaki, Akiko Masubuchi, Yorihisa Tanaka, Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharmaceutics & Drug Disposition. ,vol. 27, pp. 133- 139 ,(2006) , 10.1002/BDD.494
Takafumi Akabane, Kohichiro Tanaka, Megumi Irie, Shigeyuki Terashita, Toshio Teramura, Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica. ,vol. 41, pp. 372- 384 ,(2011) , 10.3109/00498254.2010.549970
Philip Kestell, Ingrid C. Dunlop, Michael R. McCrystal, Barrie D. Evans, James W. Paxton, Ranjith S. K. A. Gamage, Bruce C. Baguley, Plasma pharmacokinetics of N -[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial Cancer Chemotherapy and Pharmacology. ,vol. 44, pp. 45- 50 ,(1999) , 10.1007/S002800050943